Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Can artificial intelligence accelerate preclinical drug discovery and precision medicine?
Expert Opin. Drug Discov. 17, 661-665 (2022)
Precision medicine leverages molecular biomarkers for selecting optimal treatment strategies. Accordingly, stratifying patients into responder and non-responder has strongly accelerated drug discovery and drug approvals in the last two decades. Recently, the applications of artificial intelligence (AI) in healthcare have been promoting these processes, and continue to improve patient care through systematically analysing large-scale molecular data and electronic health records. In particular, preclinical pharmacogenomics data empowered AI to unfold its full potential.Areas covered: Here, we discuss the opportunities of AI in pharmacogenomics, drug discovery and precision medicine. In particular, we shed some light on the advancements in computational biomedicine from statistical, machine learning (ML) to complex deep learning (DL) models.Expert opinion: AI has already strongly impacted drug discovery, and will continue to revolutionise academic research and the pharmaceutical industry. Its algorithms aid the identification of novel treatment options through molecular signatures and thus pave the way for the next generation of precision medicine.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Artificial Intelligence ; Biomarkers ; Deep Learning ; Drug Discovery ; Machine Learning ; Pharmacogenomics ; Precision Medicine
ISSN (print) / ISBN
1746-0441
e-ISSN
1746-045X
Journal
Expert Opinion on Drug Discovery
Quellenangaben
Volume: 17,
Issue: 7,
Pages: 661-665
Publisher
Informa Healthcare
Publishing Place
London
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Computational Biology (ICB)